Results of chemo-radiation treatment for epidermoid cancer of the anal canal (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Results of chemo-radiation treatment for epidermoid cancer of the anal canal (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A683 1993. Unique Identifier : AIDSLINE ICDB/93695082
Smith D; Shah K; Rao AR; Frost D; Kagan AR; Pedadda AV; No affiliation given

Abstract: The medical records of 42 patients (pts) with a diagnosis of anal cancer treated under a standardized chemo-radiation protocol were reviewed. Chemotherapy consisted of 5-FU and mitomycin C. Radiation, concurrent with the chemotherapy for the first 4 days, consisted of 30 Gy in 15 fractions. 27 females and 15 males were treated. Five male pts were HIV-positive. Perianal cancers were excluded. Median follow-up time is 31 mo. All pts completed the treatment protocol. 12 pts (29%) had minor protocol violation. Six pts (14%) were T1 at presentation, 23 (54%) were T2, 8 (19%) were T3 and 5 (12%) were T4. Currently, 36 pts (86%) are alive without evidence of disease ( NED). Ten pts have recurred, 9 only locally (LR). Mean time to LR was 21 mo (range 2 to 52 mo). Two pts (5%) have died of intercurrent disease and 2 pts have died of anal cancer. For T1 pts, 100% are NED, LR was 17%. For T2 pts, 87% are NED, LR was 4%. For T3 pts, 75% are NED, LR was 38% and 2 pts died of their disease. For T4 pts, 60% are NED, LR was 80%. Salvage abdominoperineal resection (APR) was performed on all 9 LR. Of these 9 pts, 7 (78%) are NED with a mean follow-up of 23 mo (range 2-54 mo). There was a trend towards increased LR for female pts (33% vs 13%). Both LR and survival correlated significantly with size of tumor at presentation. APR, at present follow-up, appears to be effective salvage therapy.

Keywords: Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Anus Neoplasms/*DRUG THERAPY/MORTALITY/RADIOTHERAPY Carcinoma, Squamous Cell/*DRUG THERAPY/MORTALITY/RADIOTHERAPY Combined Modality Therapy Female Fluorouracil/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Follow-Up Studies Human HIV Seropositivity/COMPLICATIONS/MORTALITY Male Mitomycin C/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Rectal Neoplasms/*DRUG THERAPY/MORTALITY/RADIOTHERAPY Survival Rate ABSTRACT
931030
M93A0770

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .